|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Short-term restricted cash | |||||||||||||||||
| Investments | |||||||||||||||||
| Receivables, net | |||||||||||||||||
| Inventories, net | |||||||||||||||||
| Prepaid and other current assets | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||
| Goodwill | |||||||||||||||||
| Intangible assets, net of accumulated amortization of $579 and $27, respectively | |||||||||||||||||
| Goodwill and intangible assets, net | |||||||||||||||||
| Long-term restricted cash | |||||||||||||||||
| Collaboration Warrants, non-current | |||||||||||||||||
| Other long-term assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||
| Trade payables | |||||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||||
| Contract liabilities | |||||||||||||||||
| Contract loss provisions | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Debt | |||||||||||||||||
| Operating lease liabilities, non-current | |||||||||||||||||
| Warrant liabilities | |||||||||||||||||
| Other long-term liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Convertible preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares outstanding as of December 31, 2022 and 2021 | |||||||||||||||||
| Stockholders’ equity | |||||||||||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares outstanding as of March 31, 2025 and December 31, 2024 | |||||||||||||||||
| Common stock, $0.0001 par value; 500,000,000 shares authorized; 6,116,752 and 6,096,084 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | |||||||||||||||||
| Total common stock, $0.0001 par value; 500,000,000 shares authorized; 6,116,752 and 6,096,084 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||||
Loading...
